|
|
进行性加重的MOG抗体相关性脑脊髓炎合并布氏杆菌病1例报道
|
Abstract:
髓鞘少突胶质细胞糖蛋白IgG相关疾病(MOGAD)是一种神经系统脱髓鞘疾病。MOGAD的典型症状为视神经炎(ON)、脊髓炎和急性播散性脑脊髓炎(ADEM)。目前MOG抗体相关性脑脊髓炎的治疗缺乏令人信服的前瞻性研究和随机对照研究的支持，其急性期的治疗方法主要是静脉注射甲泼尼龙、免疫球蛋白或血浆置换。我们在此报告1例进行性加重的MOG抗体相关性脑脊髓炎合并布氏杆菌病患者。
Myelin oligodendrocyte glycoprotein IgG-related disease (MOGAD) is a demyelinating disorder of the nervous system. Typical symptoms of MOGAD are optic neuritis (ON), myelitis, and acute disseminated encephalomyelitis (ADEM). At present, there is a lack of convincing prospective studies and randomized controlled studies for the treatment of MOG antibody-associated encephalomyelitis, and the treatment of the acute phase is mainly intravenous methylprednisolone, immunoglobulin, or plasma exchange. We report here one patient with progressive exacerbations of MOG antibody-associated encephalomyelitis complicated with brucellosis.
| [1] | Borisow, N., Mori, M., Kuwabara, S., Scheel, M. and Paul, F. (2018) Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis. Frontiers in Neurology, 9, Article 888. https://doi.org/10.3389/fneur.2018.00888 |
| [2] | Chen, H.X., Zhang, Q., Lian, Z.Y., Liu, J., Shi, Z.Y., Miao, X.H., et al. (2017) Muscle Damage in Patients with Neuromyelitis Optica Spectrum Disorder. Neurology Neuroimmunology & Neuroinflammation, 4, e400. https://doi.org/10.1212/nxi.0000000000000400 |
| [3] | Baba, T., Nakashima, I., Kanbayashi, T., Konno, M., Takahashi, T., Fujihara, K., et al. (2009) Narcolepsy as an Initial Manifestation of Neuromyelitis Optica with Antiaquaporin-4 Antibody. Journal of Neurology, 256, 287-288. https://doi.org/10.1007/s00415-009-0139-4 |
| [4] | Uzura, Y., Takeuchi, H., Ashida, S., Fujii, C., Shishido-Hara, Y., Inaba, T., et al. (2022) A Tumefactive Anti-MOG Antibody Associated Disorder Heralding Central Nervous System B-Cell Lymphoma: Case Report on Diagnostic Challenge. Journal of Neuroimmunology, 365, 577823. https://doi.org/10.1016/j.jneuroim.2022.577823 |
| [5] | Hennes, E.M., Baumann, M., Schanda, K., Anlar, B., Bajer-Kornek, B., Blaschek, A., et al. (2017) Prognostic Relevance of MOG Antibodies in Children with an Acquired Demyelinating Syndrome. Neurology, 89, 900-908. https://doi.org/10.1212/wnl.0000000000004312 |
| [6] | Juryńczyk, M., Jacob, A., Fujihara, K. and Palace, J. (2018) Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease: Practical Considerations. Practical Neurology, 19, 187-195. https://doi.org/10.1136/practneurol-2017-001787 |
| [7] | Reindl, M. and Waters, P. (2018) Myelin Oligodendrocyte Glycoprotein Antibodies in Neurological Disease. Nature Reviews Neurology, 15, 89-102. https://doi.org/10.1038/s41582-018-0112-x |
| [8] | Avila-Calderón, E.D., Lopez-Merino, A., Sriranganathan, N., Boyle, S.M. and Contreras-Rodríguez, A. (2013) A History of the Development Ofbrucellavaccines. BioMed Research International, 2013, Article ID: 743509. https://doi.org/10.1155/2013/743509 |
| [9] | Yagupsky, P., Morata, P. and Colmenero, J.D. (2019) Laboratory Diagnosis of Human Brucellosis. Clinical Microbiology Reviews, 33, e00073-19. https://doi.org/10.1128/cmr.00073-19 |
| [10] | Akdeniz, H., Irmak, H., Anlar, ？. and Demir？z, A.P. (1998) Central Nervous System Brucellosis: Presentation, Diagnosis and Treatment. Journal of Infection, 36, 297-301. https://doi.org/10.1016/s0163-4453(98)94279-7 |
| [11] | Hou, H., Liu, X. and Peng, Q. (2019) The Advances in Brucellosis Vaccines. Vaccine, 37, 3981-3988. https://doi.org/10.1016/j.vaccine.2019.05.084 |
